Amgen stock price slips from record close as AMGN heads into earnings and the obesity-drug race
Amgen shares closed Friday down 0.7% at $344.75, after nearly reaching record highs earlier in the week. About 3.8 million shares traded hands. Investors are awaiting Amgen’s Feb. 3 earnings and updates on its obesity drug candidate, MariTide. The company’s board declared a $2.52 per share Q1 dividend, payable March 6.